Logo image of PHN.MI

PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

Europe - BIT:PHN - IT0005274094 - Common Stock

48.625 EUR
-0.33 (-0.66%)
Last: 10/20/2025, 3:00:55 PM
Fundamental Rating

7

Overall PHN gets a fundamental rating of 7 out of 10. We evaluated PHN against 13 industry peers in the Personal Care Products industry. Both the health and profitability get an excellent rating, making PHN a very profitable company, without any liquidiy or solvency issues. PHN is valued quite expensive, but it does show an excellent growth. This makes PHN very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year PHN was profitable.
PHN had a positive operating cash flow in the past year.
In the past 5 years PHN has always been profitable.
PHN had a positive operating cash flow in each of the past 5 years.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

PHN has a better Return On Assets (20.41%) than 100.00% of its industry peers.
The Return On Equity of PHN (38.54%) is better than 100.00% of its industry peers.
PHN's Return On Invested Capital of 26.24% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PHN is above the industry average of 12.37%.
The 3 year average ROIC (17.21%) for PHN is below the current ROIC(26.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROIC 26.24%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

PHN's Profit Margin of 13.48% is fine compared to the rest of the industry. PHN outperforms 76.92% of its industry peers.
PHN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 21.87%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PHN's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 97.04%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
Industry RankSector Rank
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHN is creating value.
Compared to 1 year ago, PHN has about the same amount of shares outstanding.
PHN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHN has an improved debt to assets ratio.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PHN has an Altman-Z score of 8.96. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.96, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
PHN has a debt to FCF ratio of 2.70. This is a good value and a sign of high solvency as PHN would need 2.70 years to pay back of all of its debts.
PHN has a better Debt to FCF ratio (2.70) than 69.23% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that PHN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.28, PHN is in the better half of the industry, outperforming 61.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Altman-Z 8.96
ROIC/WACC3.31
WACC7.92%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PHN has a Current Ratio of 2.06. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.06, PHN belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
PHN has a Quick Ratio of 1.75. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
PHN has a Quick ratio of 1.75. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.75
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.20% over the past year.
PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.06%.
The Revenue has been growing by 16.59% on average over the past years. This is quite good.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%

3.2 Future

PHN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.52% yearly.
PHN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.05% yearly.
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.85 indicates a rather expensive valuation of PHN.
Based on the Price/Earnings ratio, PHN is valued a bit cheaper than 76.92% of the companies in the same industry.
PHN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.42.
With a Price/Forward Earnings ratio of 20.04, PHN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than 61.54% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PHN to the average of the S&P500 Index (22.94), we can say PHN is valued inline with the index average.
Industry RankSector Rank
PE 19.85
Fwd PE 20.04
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit cheaper than the industry average as 61.54% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 76.92% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 57.46
EV/EBITDA 11.13
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of PHN may justify a higher PE ratio.
PHN's earnings are expected to grow with 13.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.24
PEG (5Y)1.36
EPS Next 2Y12.93%
EPS Next 3Y13.52%

6

5. Dividend

5.1 Amount

PHN has a Yearly Dividend Yield of 2.06%. Purely for dividend investing, there may be better candidates out there.
PHN's Dividend Yield is a higher than the industry average which is at 2.56.
Compared to an average S&P500 Dividend Yield of 2.36, PHN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.06%

5.2 History

On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

PHN pays out 40.63% of its income as dividend. This is a bit on the high side, but may be sustainable.
PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP40.63%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

PHARMANUTRA SPA

BIT:PHN (10/20/2025, 3:00:55 PM)

48.625

-0.33 (-0.66%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)09-08 2025-09-08
Earnings (Next)11-09 2025-11-09
Inst Owners17.08%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap470.69M
Analysts83.33
Price Target80.58 (65.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.06%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.98%
EPS NY rev (3m)-6.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE 19.85
Fwd PE 20.04
P/S 2.69
P/FCF 57.46
P/OCF 38.19
P/B 7.69
P/tB 12.61
EV/EBITDA 11.13
EPS(TTM)2.45
EY5.04%
EPS(NY)2.43
Fwd EY4.99%
FCF(TTM)0.85
FCFY1.74%
OCF(TTM)1.27
OCFY2.62%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)2.24
PEG (5Y)1.36
Profitability
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROCE 45.24%
ROIC 26.24%
ROICexc 32.19%
ROICexgc 49.25%
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
FCFM 4.68%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexcg growth 3Y-15.98%
ROICexcg growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Debt/EBITDA 0.4
Cap/Depr 97.13%
Cap/Sales 2.36%
Interest Coverage 250
Cash Conversion 28.97%
Profit Quality 34.7%
Current Ratio 2.06
Quick Ratio 1.75
Altman-Z 8.96
F-Score7
WACC7.92%
ROIC/WACC3.31
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.06%
EBIT Next 3Y16.37%
EBIT Next 5Y9.96%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%